Want to see SE:ACE full AI Analyst Report?
Ascelia Pharma AB (ACE) Stock Statistics & Valuation Metrics
Total Valuation
Ascelia Pharma AB has a market cap or net worth of SEK 71.84M. The enterprise value is SEK 352.94M.
- Market Cap
- SEK 71.84M
- Enterprise Value
- SEK 352.94M
Share Statistics
Ascelia Pharma AB has 133,535,460 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 133,535,460
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Ascelia Pharma AB’s return on equity (ROE) is -0.77 and return on invested capital (ROIC) is -73.35%.
- Return on Equity (ROE)
- -0.77
- Return on Assets (ROA)
- -0.68
- Return on Invested Capital (ROIC)
- -73.35%
- Return on Capital Employed (ROCE)
- -0.74
- Revenue Per Employee
- 0
- Profits Per Employee
- -7.63M
- Employee Count
- 10
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Ascelia Pharma AB is -1.06. Ascelia Pharma AB’s PEG ratio is -0.01.
- PE Ratio
- -1.06
- PS Ratio
- 0.00
- PB Ratio
- 0.75
- Price to FCF
- -1.02
- Price to Operating Cash Flow
- -1.00
- PEG Ratio
- -0.01
Income Statement
In the last 12 months, Ascelia Pharma AB had revenue of 0 and earned -76.25M in profits. Earnings per share was -0.67.
- Revenue
- 0
- Gross Profit
- -888.00K
- Operating Income
- -74.13M
- Pretax Income
- -76.72M
- Net Income
- -76.25M
- EBITDA
- -73.24M
- Earnings Per Share (EPS)
- -0.67
Cash Flow
In the last 12 months, operating cash flow was -67.19M and capital expenditures 0, giving a free cash flow of -67.19M billion.
- Operating Cash Flow
- -67.19M
- Free Cash Flow
- -67.19M
- Free Cash Flow per Share
- -0.51
Dividends & Yields
Ascelia Pharma AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -98.47%
- Earnings Yield
- -89.19%
Stock Price Statistics
- Beta
- 0.64
- 52-Week Price Change
- -83.41%
- 50-Day Moving Average
- 0.63
- 200-Day Moving Average
- 1.95
- Relative Strength Index (RSI)
- 42.12
- Average Volume (3m)
- 991.29K
Important Dates
Ascelia Pharma AB upcoming earnings date is Nov 05, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Nov 05, 2026
- Ex-Dividend Date
- ―
Financial Position
Ascelia Pharma AB as a current ratio of 4.35, with Debt / Equity ratio of 1.05%
- Current Ratio
- 4.35
- Quick Ratio
- 4.35
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.67
- Interest Coverage Ratio
- -13.46
Taxes
In the past 12 months, Ascelia Pharma AB has paid -468.00K in taxes.
- Income Tax
- -468.00K
- Effective Tax Rate
- 0.01
Enterprise Valuation
Ascelia Pharma AB EV to EBITDA ratio is -0.51, with an EV/FCF ratio of -0.46.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.51
- EV to Free Cash Flow
- -0.46
- EV to Operating Cash Flow
- -0.46
Balance Sheet
Ascelia Pharma AB has SEK 38.05M in cash and marketable securities with SEK 490.00K in debt, giving a net cash position of SEK 37.56M billion.
- Cash & Marketable Securities
- SEK 38.05M
- Total Debt
- SEK 490.00K
- Net Cash
- SEK 37.56M
- Net Cash Per Share
- SEK 0.28
- Tangible Book Value Per Share
- SEK 0.25
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Ascelia Pharma AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 58.15%
Scores
- Smart Score
- ―
- AI Score
- 44
